Document Detail


Comparison of peginterferon and interferon in treating Chinese patients with chronic hepatitis C.
MedLine Citation:
PMID:  18705326     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND/AIMS: Higher virological and biochemical response rates were obtained in many clinical trials in Caucasian patients with chronic hepatitis C (CHC) after treating with peginterferon than in those with interferon. However, it is not clear whether this conclusion can be extrapolated to patients with Chinese ethnic origin and which type of peginterferon or interferon was more effective in treating Chinese CHC patients? The aim of this study was to perform a meta-analysis of randomized controlled trials (RCT) and compare peginterferon with interferon in treating Chinese patients with CHC. METHODOLOGY: The outcome measures were virological response (end-of-treatment virological response (ETVR) and sustained virological response (SVR)). Biochemical response (end-of-treatment biochemical response (ETBR) and sustained biochemical response (SBR) were also introduced as supplement to the evaluation on effect of peginterferon and interferon in treating Chinese patients with CHC. The measure of association employed was relative risk (RR) calculated by the random-effect model, with heterogeneity, sensitivity and subgroup analyses. RESULTS: Of the 110 studies screened, 5 RCTs including 499 patients (peginterferon 258, interferon 241) were analyzed. SVR and SBR obtained in patients treated with peginterferon were significantly higher than patients treated with interferon (60% vs. 35.53%, RR, 1.95; 95% confidence interval (CI), 1.17-3.24; p<0.05; 57.30% vs. 40.38%, RR, 1.36; 95% CI, 1.08-1.71; p<0.05), but the difference is not evident in ETVR and ETBR. In the subgroup analyses, ETVR and SVR obtained in patients treated with peginterferon alpha-2a (79.75% and 48.1%) were significantly higher than with interferon alpha-2a (35.37% vs. 19.05%, RR, 2.51; 95% CI, 1.74-3.63; p<0.05), but the difference is not evident between peginterferon alpha-2b and interferon alpha-2b. SBR obtained with peginterferon was also significantly higher than with interferon (57.3% vs. 40.38%, RR, 1.36; 95% CI, 1.08-1.71; p<0.05), but the difference is not evident in EBVR. Higher SVR were obtained in genotype 1 Chinese patients treated with peginterferon compared with those treated with interferon (48.45% vs. 23.24%, RR, 2.00; 95% CI, 1.48-2.7; p<0.01), but the ETVR were similar. The effects of peginterferon and interferon in genotype non-1 patients were also similar. Higher ETVR and SVR were obtained in patients treated with peginterferon alpha-2b compared with those treated with peginterferon alpha-2a (97.56% vs. 79.75% and 82.93% vs. 56.96%; p<0.05 and p<0.01, respectively). SVR obtained in patients treated with peginterferon alpha-2b were significantly higher than those treated with peginterferon alpha-2a (73.53% vs. 41.73%, p<0.01) in treating genotype 1 Chinese patients, but the superiority didn't appear in treating genotype non-1 patients. CONCLUSIONS: Both peginterferon alpha-2a and peginterferon alpha-2b might be recommended for Chinese ethnic original patients with CHC. Peginterferon alpha-2b might be more effective, with an expected relative higher virological response and biochemical response, in treating Chinese CHC patients.
Authors:
Sihai Zhao; Enqi Liu; Haibo Yu; Haojie Yang; Meng Xun; Xin Xue; Juan Song; Kun Xu; Yonglie Chu
Related Documents :
2285296 - Chloramphenicol concentrations in sera of patients with typhoid fever being treated wit...
21903986 - Interaction of time-varying albumin and phosphorus on mortality in incident dialysis pa...
6195826 - Psoriasis therapy: a current perspective.
1288546 - Psoriatic arthritis treated with cyclosporin a.
22236006 - Carriage of the egf rs4444903 a>g functional polymorphism associates with disease progr...
7882786 - Unsuspected sphincter defects shown by anal endosonography after anorectal surgery. a p...
Publication Detail:
Type:  Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Hepato-gastroenterology     Volume:  55     ISSN:  0172-6390     ISO Abbreviation:  Hepatogastroenterology     Publication Date:    2008 May-Jun
Date Detail:
Created Date:  2008-08-18     Completed Date:  2008-12-19     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8007849     Medline TA:  Hepatogastroenterology     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  1047-54     Citation Subset:  IM    
Affiliation:
Department of Immunology and Microbiology, Xi'an Jiaotong University School of Medicine, Shaanxi 710061, China. zhaosihai123@hotmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antiviral Agents / adverse effects,  therapeutic use*
Dose-Response Relationship, Drug
Hepatitis C, Chronic / diagnosis,  drug therapy*,  ethnology
Humans
Interferon Alfa-2a / adverse effects,  therapeutic use*
Interferon Alfa-2b / adverse effects,  therapeutic use*
Polyethylene Glycols / adverse effects,  therapeutic use*
Randomized Controlled Trials as Topic
Chemical
Reg. No./Substance:
0/Antiviral Agents; 0/Polyethylene Glycols; 0/peginterferon alfa-2a; 0/peginterferon alfa-2b; 76543-88-9/Interferon Alfa-2a; 99210-65-8/Interferon Alfa-2b

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Oily chemoembolization combined with degradable starch microspheres for HCC with cirrhosis.
Next Document:  Model for end-stage liver disease (MELD) score for predicting late esophageal varices rebleeding in ...